Study Results from QILU University of Technology Provide New Insights into Human Serum Albumin Therapy (Photodynamic and Photothermal Therapy Via Human Serum Albumin Delivery).

A study conducted at QILU University of Technology in Jinan, People's Republic of China, explores the use of Human Serum Albumin (HSA) as a carrier for photodynamic and photothermal therapy in tumor treatment. The research highlights the advantages of HSA delivery in targeted therapy with less trauma, but also notes limitations such as the dependence on dosage and tissue penetration. The study aims to enhance photosensitizers and photothermal converting agents for improved cancer diagnosis and treatment. [Extracted from the article]